Cogent Biosciences, Inc

Opexa Therapeutics is a biotechnology company that specializes in the development of patient-specific cellular therapies for the treatment of autoimmune diseases, such as multiple sclerosis and diabetes. It offers Tovaxin, which is a vaccine for early relapsing multiple sclerosis. The company also offers an adult stem cell program that enables the production of multipotent cells generated from patients white blood cells and provides means to differentiate these stem cells into other tissue types. Opexa Therapeutics offers solutions that minimize the threat of treatment rejection. It operates clinical advisory boards for multiple sclerosis and diabetes that take care of the supervision of related procedures. The company provides products to target individual s disease progression and modification.

Decibel Therapeutics, Inc. is a Boston-based biotechnology company that is dedicated to addressing the unmet needs of individuals with hearing and balance disorders. With a focus on regenerative and gene therapy strategies, Decibel aims to develop novel therapeutics that can restore hearing and balance, creating meaningful connections for patients and their families. Driven by a passionate team, Decibel Therapeutics is at the forefront of fueling a new field in drug development. Through their pipeline of innovative approaches, including genetic testing resources, the company is committed to making a significant impact in the lives of those affected by hearing and balance disorders.Generated from the website

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.